Amgen reports additional Phase IIIb data for episodic migraine candidate

Amgen Inc. (NASDAQ:AMGN) reported additional data from the Phase IIIb LIBERTY trial to prevent episodic migraine showing that 30.3% of patients who received Aimovig erenumab (AMG 334) achieved at least a 50% reduction

Read the full 335 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE